Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligand
Open Access
- 26 May 2025
- journal article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (10) , 5036-5049
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Foundation for the National Institutes of Health (AA028007, U01AA014106)
- National Institutes of Health (AA028007, U01AA014106)
- School of Medicine, Emory University
- National Cancer Institute (T32CA275777)
This publication has 50 references indexed in Scilit:
- Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primatesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumoursEuropean Journal of Medicinal Chemistry, 2022
- Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2European Journal of Medicinal Chemistry, 2022
- Imaging the trace amine-associated receptor 1 by positron emission tomographyTetrahedron Letters, 2021
- Avoid the trap: Targeting PARP1 beyond human malignancyCell Chemical Biology, 2021
- Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseasesLife Sciences, 2021
- Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[11C]methoxyphenethyl)pyridazin-3(2H)-one, a 11C-labeled -amino acid oxidase (DAAO) inhibitor for PET imagingBioorganic & Medicinal Chemistry Letters, 2020
- Chemistry for Positron Emission Tomography: Recent Advances in 11C‐, 18F‐, 13N‐, and 15O‐Labeling ReactionsAngewandte Chemie International Edition, 2019
- Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomographyJournal of Fluorine Chemistry, 2006
- Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agentsMolecular Imaging and Biology, 2003